Nektar Therapeutics (NKTR) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Nektar Therapeutics (NKTR) advanced +1.63% to $39.18, trading at 8% of its 52-week range ($33.4 – $109). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Nektarâs rezpegaldesleukin enters phase 3 in atopic dermatitis, with Q1 2027 data ahead. Discover more here on NKTR and our bullish thesis for the stock.
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-based financial markets. Howard Robin, Preside
Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -43.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NKTR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NKTR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Nektar Therapeutics (NKTR) ranks #860 by composite RQD confidence (33/100, grade E) and #322 by equity capitalization ($1.34B). Within this direct 5-issuer industry benchmark cohort, NKTR leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with NKTR at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NKTR
ACTIVE
Nektar Therapeutics | E | 33/100 | — | 96.0% | -35.0% | +1.63% | $1.34B | Benchmark Subject |
| KARD Kardigan Inc. | C- | 61/100 | — | — | — | +4.22% | $1.34B | /kard-vs-nktr → |
| DMRA Damora Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +1.85% | $1.36B | /dmra-vs-nktr → |
| OMER Omeros Corporation | D | 46/100 | — | — | -35.0% | +5.98% | $1.37B | /omer-vs-nktr → |
| KRSA Korsana Biosciences Inc. | E | 33/100 | — | — | -5.7% | +0.37% | $1.38B | /krsa-vs-nktr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nektar Therapeutics (NKTR) reported GAAP revenue of $55.2M (-43.9% vs. FY2024 revenue of $98.4M , and -38.7% cumulative change since FY2023) , GAAP net income of -$164.0M, operating cash flow of -$208.5M, and free cash flow of -$208.7M (-17.8% YoY). On the balance sheet, NKTR closed FY2025 with $280.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $55.2M | -$164.0M | -$208.5M | -$208.7M | $280.4M | — |
| FY2024 (FY) | 2024-12-31 | $98.4M | -$119.0M | -$175.7M | -$177.2M | $303.9M | — |
| FY2023 (FY) | 2023-12-31 | $90.1M | -$276.0M | -$192.6M | -$192.6M | — | — |
As of 2026-11-01, Nektar Therapeutics (NASDAQ: NKTR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $39.18 (+1.63% 1D, market cap $1.34B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NKTR ranks #860 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NKTR carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, KARD (Kardigan Inc.) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $1.34B) and DMRA (Damora Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.36B). Among the 5-stock peer group, NKTR leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).
Per NKTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000906709), Nektar Therapeutics generated $55.2M in revenue (-43.9% YoY), -$164.0M in net income, and -$208.7M in free cash flow against $280.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NKTR last traded at $39.18 (+1.63% on volume of 490,385 shares), positioning the stock -29.65% below its 50-day simple moving average ($55.69) and -39.73% below its 200-day simple moving average ($65.01). Across its 52-week range of $33.40 to $109.00, NKTR sits at the 7.6% percentile with a 14-day RSI of 34.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($35.18 to $43.18).
Why NKTR Stock advanced +1.63% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.